Avacta Share Discussion Threads

[the drewster] 08/11/2018 07:31

Unlikely ... this does look cautiously promising.

[lantanatony] 07/11/2018 18:57

Perhaps all the good guys have left!?

[the drewster] 07/11/2018 17:02

Recruiting at both sites ... encouraging.

[lantanatony] 03/11/2018 12:10

Yes
The race is on, but are Avacta at the Races?!

[1i1i1i] 02/11/2018 09:16

Competitive LandscapeThe global scaffold technology market is characterized by the presence of well-diversified international and small and medium-sized vendors. These companies are consistently launching new products to enhance their offerings in the market. With the advancement of technologies, companies are innovating and introducing new customized products to cater the growing needs of the customers. Leading companies are also acquiring other companies, and enhancing their product offerings to improve their market reach. Acquisitions enable key players to increase their market potential in terms of geographic expansion and expansion of customer base

[1i1i1i] 15/10/2018 17:39

Hefty 80,000 buy near close.

[hampton58] 12/10/2018 11:13

The San Diego conference presentation will only highlight the huge potential and continued upwards momentum in this area and hence Tuffts and now commercial relationship having been signed over the last week.More to come .

[bscuit] 12/10/2018 00:07

As a Reach announcement it shouldn't have been shown as an RNS

[1i1i1i] 11/10/2018 18:58

Yep, you bought at the wrong time, happens to us all.

[contact2fsnetcouk] 11/10/2018 18:28

£1.20 - oh dear, I will not make much on these.

Was buying at 80p + but wouldn't touch with a barge pole now.

Were they not tipped to reach £2 a few months ago?

Yours

Disappointed

[1i1i1i] 11/10/2018 07:11

Avacta Group PLC Avacta's CTO to Present at Major US ConferenceSource: RNS Non-RegulatoryTIDMAVCTAvacta Group PLC11 October 201811 October 2018Avacta Group plc("Avacta" or "the Group" or "the Company")Avacta's Chief Technology Officer to Present at Major US ConferenceAvacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that its Chief Technology Officer, Dr Matt Johnson, will be presenting new data for Affimer research tools and diagnostics reagents at the Biomarkers and Precision Medicine Congress in San Diego on the 12 October 2018.Dr Johnson will be presenting recent data showing how the Affimer technology can be used to simplify diagnostics and other immunoassays.The data that Dr Johnson will present shows that immunoassays built using Affimers perform as well as, and in many cases better than, equivalent assays built using antibodies. These data are critical in driving the adoption of the new Affimer technology in a huge market that is dominated by antibodies.In the second part of his presentation, Dr Johnson will speak about an innovative class of Affimers that captures antibodies but only when the antibodies are bound to their own targets. This offers a route to improving an important type of diagnostic test to have a more specific and clearer result. The commercial potential for this class of Affimer is significant.- Ends -For further information from Avacta Group plc, please contact: Avacta Group plc Tel: [phone] Alastair Smith, Chief Executive Officer www.avacta.com Tony Gardiner, Chief Financial Officer finnCap Ltd Tel: [phone] Geoff Nash / Giles Rolls - Nominated www.finncap.com Adviser Tim Redfern - Corporate Broking Tel: [phone] WG Partners Tel: [phone] Nigel Birks / Nigel Barnes www.wgpartners.co.uk David Wilson / Claes Spang Zyme Communications (Trade and Regional Tel: [phone] Media) [e-mail] Katie Odgaard Yellow Jersey (Financial Media and Tel: [phone] IR) Tel: [phone] Sarah Hollins [e-mail] Katie Bairsto About Avacta Group plc (www.avacta.com)Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.ENDNRAFKKDKKBDBBKD(END) Dow Jones NewswiresOctober 11, 2018 02:00 ET (06:00 GMT)

[lantanatony] 10/10/2018 19:37

More jam tomorrow stuff from Avacta.
Once again no real disclosure on the deal detail but just enough to depress the share price!

[1i1i1i] 10/10/2018 14:08

https://www.google.co.uk/amp/s/www.proactiveinvestors.co.uk/companies/amp/news/206741£1.20 target

[hampton58] 10/10/2018 08:51

With today's deal highlighting the upside potential there is on the Licensing side and off the validation of Tuffts Medical School, this brings the company into tier one going forward as this will only be the first of these deals.Come end of the month this stock will be trading at a substantial premium to current level.

[the drewster] 10/10/2018 08:27

Agree Spekky - common across aim.

[spekky] 10/10/2018 08:23

There is a level of mistrust (of the board) here that is going to be hard to overcome.

[dave4545] 10/10/2018 08:14

Under 25.5p to buy so some sells are actually buys. It's like getting blood out of a stone in this market atm

I wonder what the price would do now if it issued the same news as it did when it
went to 45p ish intraday on the last spike, struggle to get over 30p ??

[nobbygnome] 10/10/2018 08:10

It always surprises me the level of sells after a good announcement. Yes I know the mantra is buy the story, sell the news but it is hardly the case the price has gone up here ahead of the announcement.

Aim is a casino......I guess you just have to play it to your advantage.

[nobbygnome] 10/10/2018 07:56

>> pug

Fair summary I think....but nevertheless it looks undervalued to me.

[dave4545] 10/10/2018 07:56

Nice to see some positive news here.

[pugugly] 10/10/2018 07:51

Nobby & Timbo - You both here too - Lots of potential but still foggy ahead cashwise - but potentially (imo) worth the small nibble already taken.

[nobbygnome] 10/10/2018 07:43

25-27 pre market bodes well for the day....

[the drewster] 10/10/2018 07:39

PD-L1 Lag3 is massively interesting globally. Progress on that front will send the shares into the stratosphere.

Meanwhile, deals like the one announced today increase the likelihood that no more funding rounds will further limit our ultimate profits!

[1i1i1i] 10/10/2018 07:11

Affimer technology is going to be revolutionary, this is just the beginning, exciting time to be here with such a tiny market cap.